Literature DB >> 16790519

Bevacizumab is active in malignant effusion.

O Pichelmayer, B Gruenberger, C Zielinski, M Raderer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16790519     DOI： 10.1093/annonc/mdl143

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  19 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Differential expression of vascular endothelial growth factor-A, -C and -D for the diagnosis and prognosis of cancer patients with malignant effusions.

Authors:  Lin Jia; Yun DU; Tao Li; Yalei Lv; Yudong Wang; Yan Zhang; Xinliang Zhou; Wei Liu
Journal:  Oncol Lett       Date:  2015-06-02       Impact factor: 2.967

3.  Chloroquine inhibits tumor growth and angiogenesis in malignant pleural effusion.

Authors:  Qian Li; Dong-Mei Yuan; Li-Hong Ma; Chen-Hui Ma; Ya-Fang Liu; Tang-Feng Lv; Yong Song
Journal:  Tumour Biol       Date:  2016-10-22

4.  Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.

Authors:  Motohiro Tamiya; Akihiro Tamiya; Tadahiro Yamadori; Keiko Nakao; Kazuhiro Asami; Tomomi Yasue; Tomoyuki Otsuka; Takayuki Shiroyama; Naoko Morishita; Hidekazu Suzuki; Norio Okamoto; Kyoichi Okishio; Tomoya Kawaguchi; Shinji Atagi; Ichiro Kawase; Tomonori Hirashima
Journal:  Med Oncol       Date:  2013-08-08       Impact factor: 3.064

Review 5.  Malignant pleural effusion: tumor-host interactions unleashed.

Authors:  Georgios T Stathopoulos; Ioannis Kalomenidis
Journal:  Am J Respir Crit Care Med       Date:  2012-05-31       Impact factor: 21.405

6.  Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.

Authors:  Hui Zhao; Xiaosong Li; Dianjun Chen; Jianhua Cai; Yan Fu; Huanrong Kang; Jie Gao; Ke Gao; Nan Du
Journal:  Med Oncol       Date:  2015-01-22       Impact factor: 3.064

7.  PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.

Authors:  Boris Winterhoff; Luisa Freyer; Edward Hammond; Shailendra Giri; Susmita Mondal; Debarshi Roy; Attila Teoman; Sally A Mullany; Robert Hoffmann; Antonia von Bismarck; Jeremy Chien; Matthew S Block; Michael Millward; Darryn Bampton; Keith Dredge; Viji Shridhar
Journal:  Eur J Cancer       Date:  2015-03-05       Impact factor: 9.162

Review 8.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

Review 9.  Management of malignant pleural effusion.

Authors:  Hongbin Chen; Julie Brahmer
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

Review 10.  VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.

Authors:  Elizabeth R Gerstner; Dan G Duda; Emmanuelle di Tomaso; Peter A Ryg; Jay S Loeffler; A Gregory Sorensen; Percy Ivy; Rakesh K Jain; Tracy T Batchelor
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.